Loading...
Market
Story
Eli Lilly Receives FDA Approval for Alzheimer's Drug Kisunla on Tuesday, Stock Nears $1 Trillion
Jul 3, 2024, 06:10 AM
Eli Lilly & Co. has received approval from the U.S. Food and Drug Administration (FDA) on Tuesday for its new amyloid-targeting therapy, Kisunla, to treat adults with early symptomatic Alzheimer's Disease. This approval positions Eli Lilly to launch the drug at a premium price, citing its higher efficiency compared to existing treatments like Leqembi, introduced last year by Eisai and Biogen. Analysts have provided mixed reviews, with Jefferies rating it a 'buy' with a price target of $906.71, while BMO Capital Markets rated it 'outperform' with a price target of $914.37. The approval has driven Eli Lilly's stock to new highs, nearing a $1 trillion market cap.
View original story
Similar markets
$45.4 billion to $46.6 billion • 25%
Less than $45.4 billion • 25%
More than $46.6 billion • 25%
Between $46.0 billion and $46.6 billion • 25%
Below $45 billion • 25%
$45 billion to $45.5 billion • 25%
$45.5 billion to $46 billion • 25%
Above $46 billion • 25%
Below $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
Above $12 billion • 25%
10-15% • 25%
0-5% • 25%
5-10% • 25%
15% or more • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Below 10% • 25%
10% to 15% • 25%
15% to 20% • 25%
Above 20% • 25%